Effect of ultrasound-guided fascial plane block (UGPB) on pain control of rib fractures: a systematic review and meta-analysis Authors: Yinping Ge, Zhengfang Liu, Weichun Wu, Ming Zhang, Yun Gan Published: 2026 ABSTRACT BackgroundEffective pain management for rib fractures is crucial to prevent pulmonary complications and facilitate recovery. UGPB has emerged as a promising regional analgesic technique for these patients.ObjectiveThis systematic review with meta-analysis aims to evaluate the effectiveness of UGPB compared with standard care for managing pain associated with rib fractures. In this review, the term UGPB serves as an umbrella term for various UGPBs, with the erector spinae plane block (ESPB) and serratus anterior plane block (SAPB) being the two specific techniques evaluated in the included studies.MethodsThis study conducted a comprehensive search of electronic databases including PubMed, Embase, Cochrane Library, Web of science and China National Knowledge Infrastructure (CNKI) up to 31 March 2026. Eligibility criteria were established based on the inclusion of adult patients diagnosed with rib fractures treated with UGPB versus standard care. The primary outcome was pain intensity, assessed using a Visual Analog Scale (VAS) or Numeric Rating Scale (NRS). Secondary outcomes included total amount of analgesic consumption, respiratory function (PaO₂ and PaCO₂ via arterial blood gas analysis), and adverse events. Risk of bias was assessed using the Cochrane Risk of Bias (RoB 2) tool. The certainty of evidence for primary outcomes was assessed using the GRADE framework. Continuous outcomes were pooled as standardized mean differences (SMD) with 95% confidence intervals using a random-effects model; heterogeneity was assessed via I².ResultsNine randomized controlled trials (RCTs) involving 664 participants were included. Most studies raised some concerns regarding risk of bias, primarily related to the randomization process, allocation concealment, or blinding of participants and personnel; four studies were judged to be at high overall risk of bias, and none at low risk. The pooled data from 7 studies (423 participants) showed that UGPB significantly reduced pain scores (SMD = -0.44, 95% CI: -0.72 to -0.16; I² = 51%; p < 0.01). A leave-one-out sensitivity analysis for pain scores (excluding one study at a time from the 7 included studies) yielded SMDs ranging from − 0.49 to -0.38 (all p < 0.05) and I² ranging from 45% to 58%, confirming the robustness of this finding. For respiratory parameters, based on 3 studies (198 participants) there were no significant differences in PaCO₂ levels (SMD = -0.02, 95% CI: -0.56 to 0.61; I² = 75%; p = 0.95). PaO₂ levels remained stable (SMD = 0.04, 95% CI: -0.24 to 0.32; I² = 0%; p = 0.78). The effect on analgesic consumption, from 7 studies (546 participants), was not significant (SMD = -0.09, 95% CI: -1.61 to 1.43; I² = 96%; p = 0.91). The certainty of evidence was low for pain scores and very low for analgesic consumption and blood gas parameters according to GRADE.ConclusionUGPB reduces pain scores in patients with rib fractures, with a small-to-moderate effect size (SMD = -0.44, 95% CI: -0.72 to -0.16), and does not appear to compromise respiratory function based on stable PaCO₂ and PaO₂ levels. However, given the concerns regarding risk of bias and heterogeneity, these findings should be interpreted cautiously. High heterogeneity in analgesic consumption and other outcomes underscores the need for further high-quality research to standardize protocols and optimize the use of UGPB in clinical practice.PROSPERO registrationCRD420251077539 (registered 20 June 2025) Supplementary InformationThe online version contains supplementary material available at 10.1186/s12871-026-04045-x. Introduction Rib fractures are among the most common injuries in chest trauma, accounting for approximately 10–15% of all chest injuries [1]. More than that, it has been rising in incidence over the past decade, with one large U.S. registry reporting a 52% increase from 2010 to 2020 [2].With changes in modern lifestyles, particularly the increase in high-energy trauma events such as traffic accidents falls, and other accidents, the incidence of rib fractures has been rising annually [3]. Rib fractures not only cause significant pain to patients but may also lead to a series of severe complications, such as pulmonary infections, respiratory failure, and chronic pain, which can severely impact patients’ quality of life and prognosis [4]. Clinically, the main symptoms of rib fractures include intense chest pain, which worsens with deep breathing, coughing, or movement [5]. This pain not only makes normal breathing difficult for patients but may also lead to decreased lung function, increasing the risk of pneumonia and respiratory failure. Additionally, persistent pain may result in anxiety and sleep disturbances [6], further affecting recovery, and these injuries also carry a high risk of pulmonary complications -- such as pneumonia, respiratory failure, and chronic pain -- that significantly worsen long-term outcomes [7, 8]. Traditional systemic analgesics, including opioids and non-steroidal anti-inflammatory drugs (NSAIDs), often fail to provide adequate pain control and are associated with adverse effects like nausea, vomiting, constipation, and sedation [9]. Thus, timely and effective pain relief is a critical component of rib fracture treatment. Traditional pain relief methods include oral analgesics and intravenous analgesics; however, these often fail to fully control pain and may come with various side effects such as nausea, vomiting, constipation, and drowsiness [10], prompting interest in regional techniques [9]. Traditional regional techniques for rib fractures, such as landmark-based thoracic paravertebral or epidural blocks, have been used for decades [11, 12]. While effective, these blind or landmark-based approaches carry inherent risks, including pneumothorax and inadvertent vascular or neural puncture, due to their proximity to critical structures and the lack of direct visualization. The advent of ultrasound-guided fascial plane blocks (UGPBs), such as the Erector Spinae Plane Block (ESPB) first described in 2016 and the Serratus Anterior Plane Block (SAPB) introduced earlier, represented a paradigm shift [11, 12]. These techniques utilize real-time ultrasonography to visualize the needle tip and local anesthetic spread within a relatively safe fascial plane, remote from the pleura and major neurovascular bundles, thereby potentially enhancing safety and simplifying the procedure [12, 13]. Despite rapid clinical adoption and numerous studies reporting on the efficacy of UGPBs, the evidence remains fragmented [14–16]. Variations in study outcomes, block techniques, and patient populations create uncertainty. Therefore, a systematic review and meta-analysis are warranted to synthesize the existing evidence, quantify the analgesic benefit, and evaluate the impact on respiratory function to provide robust guidance for clinical practice [17]. In recent years, the development of regional anesthesia techniques has offered new options for pain management in rib fractures [11]. Ultrasound-guided plane block is an emerging local anesthesia technique that uses ultrasound imaging to accurately locate nerve structures and inject local anesthetics into the target area, achieving effective pain relief. Compared to traditional blind techniques or anatomical landmark-based approaches, ultrasound-guided plane block offers greater accuracy and safety, reducing the incidence of complications. Currently, commonly used plane block techniques include the Erector Spinae Plane Block (ESPB) and Serratus Anterior Plane Block (SAPB) [9]. These techniques have demonstrated considerable efficacy across various pain management contexts [9], with particular success in alleviating pain from rib fractures. Evidence suggests that ultrasound-guided plane block not only provides significant analgesia but also enhances patient comfort and facilitates early mobilization and recovery. However, the existing literature on ultrasound-guided plane blocks for rib fracture pain presents discrepancies, with studies often limited by small sample sizes and yielding inconsistent conclusions [18]. For instance, while some trials report significant pain reduction and opioid-sparing effects with techniques such as the erector spinae plane block [14] or serratus anterior plane block [15], others suggest that the analgesic profile may vary depending on the specific block type and timing of assessment [19]. This recognized need for a comprehensive and up-to-date synthesis of the evidence has been further highlighted in a recently published systematic review protocol on this topic [17]. Therefore, the present study aims to systematically evaluate the effectiveness of UGPB compared with standard care (i.e., systemic analgesia) for pain management in patients with rib fractures through a meta-analysis, in order to provide more robust and clinically informative evidence. Methods Study design This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [20]. The protocol for this systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) on 20 June 2025 (registration number CRD420251077539). The full protocol is accessible at: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251077539. Search strategy This study searched five databases: PubMed, Embase, Web of Science, Cochrane Central, and China National Knowledge Infrastructure (CNKI), covering relevant studies from their inception up to 31 March 2026. The search strategy combined subject terms and free-text terms, including keywords such as “plane block,” “rib fractures,” and related terms or synonyms using Boolean operators (AND, OR). Filters for study type (Randomized Controlled Trial) and population (adults, humans) were applied where available. A systematic search of grey literature (e.g., clinical trial registries, conference proceedings) was not conducted, as the review focused on peer-reviewed, published evidence. Additionally, this research reviewed the references of the included studies to identify further relevant literature. Detailed search strategies for each database are presented in Supplementary Table 1. Inclusion and exclusion criteria Studies were eligible for inclusion if they were randomized controlled trials (RCTs) involving adult patients (≥ 18 years) diagnosed with rib fractures. The intervention of interest was any UGPB, including but not limited to the erector spinae plane block (ESPB) and serratus anterior plane block (SAPB), compared to a control group receiving standard care (i.e., systemic analgesic regimens such as opioids, non-steroidal anti-inflammatory drugs, or acetaminophen) without such a block. The primary outcome of interest was pain intensity, with secondary outcomes including analgesic consumption, arterial blood gas parameters (PaO₂ and PaCO₂), and adverse events. Studies were excluded for the following reasons: (1) studies where the intervention involved a non-fascial plane block technique (e.g., traditional paravertebral or epidural block) or a mixed intervention where the effect of the fascial plane block could not be isolated; (2) studies reporting on overlapping or duplicated patient populations; (3) studies with incomplete outcome data that could not be obtained after attempting to contact the corresponding authors; and (4) studies that did not report at least one of the predefined primary or secondary outcomes (pain intensity, analgesic consumption, arterial blood gas parameters, or adverse events). Outcomes and measurement The primary outcome was pain intensity, assessed using a self-reported Visual Analog Scale (VAS, 0–100 mm) or Numeric Rating Scale (NRS, 0–10) [21]. Data were extracted for the following post-intervention time points: immediate (2–4 h), early (24 h), and when available, at 48 h. Secondary outcomes included Analgesic consumption Reported as total morphine milligram equivalents (MME) for opioid analgesics within the first 24 h, or the total volume/consumption of other analgesics when MME was not applicable. Respiratory function Assessed via arterial blood gas analysis, specifically Partial Pressure of Oxygen (PaO₂) and Partial Pressure of Carbon Dioxide (PaCO₂), measured at the time point closest to 24 h post-intervention. Adverse events Documented as the incidence (number of events or participants with events) of predefined complications, including nausea, vomiting, pruritus, respiratory depression, local anesthetic systemic toxicity, and pneumothorax. Literature screening and data extraction Two reviewers independently screened the titles and abstracts of all retrieved records for inclusion. Any disagreements were resolved by consensus discussion or, if needed, by consultation with a third reviewer. No AI-assisted screening tools were used. For studies with incomplete information or missing outcome data, corresponding authors were contacted via email for clarification. A maximum of two reminder emails were sent at two-week intervals. If no response was received within four weeks, the study was excluded from the meta-analysis. No imputation or statistical estimation was performed for missing data; all analyses were based on available complete data. The following data were extracted: study design, baseline characteristics of the control and intervention groups, and outcome measures (pain scores, analgesic consumption, PaO₂, PaCO₂, and adverse events). For pain scores, data were extracted at the earliest reported post-block time point to assess immediate analgesic effect; the 24-hour time point was prioritized when multiple time points were reported to evaluate sustained analgesia. Arterial blood gas analysis data were extracted at the time point closest to 24 h post-intervention. If any discrepancies in data were found, a third researcher re-evaluated the information. Risk of bias assessment Two reviewers (Ge and Liu) independently evaluated the risk of bias in each study using the Cochrane Risk of Bias Assessment 2.0 Tool [22] and its standard algorithm/template, which covers the following domains: randomization process, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other potential biases. The overall risk of bias classification (low risk, some concerns, or high risk) for each study was determined according to the Cochrane RoB 2 algorithm [22]. Any disagreements between the reviewers were systematically documented and subsequently resolved through a consensus discussion. In cases where consensus could not be reached, a third researcher was consulted to adjudicate and make a final decision. GRADE assessment The certainty of the evidence for the primary outcomes (pain scores, analgesic consumption, PaO₂, PaCO₂) was assessed by two reviewers using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Evidence from randomized trials starts as high certainty but can be rated down for risk of bias, inconsistency, indirectness, imprecision, and publication bias. Discrepancies were resolved by consensus. Statistical methods Meta-analyses were performed using R Studio (version 2025.09.1 + 401; RStudio, PBC) with the meta and metafor packages, and Stata (version 19.5; StataCorp LLC) with the meta package. For all continuous outcomes, the standardized mean difference (SMD) was selected as the summary effect measure, presented with its 95% confidence interval (CI). The SMD served as the primary effect size estimator. The 95% CI was interpreted as the range of plausible values for the true effect, with clinical relevance assessed by considering both the point estimate and the width of the interval. This choice was made a priori, primarily to allow for the pooling of analgesic consumption data, which were anticipated to be reported on different scales. To maintain methodological consistency, the SMD was also applied to pain scores and blood gas parameters. The magnitude of the SMD was interpreted using conventional thresholds for clinical importance: SMD ≤ 0.5 as a small effect, SMD between 0.5 and 0.8 as a medium effect, and SMD ≥ 0.8 as a large effect [23]. Heterogeneity was quantified using the I² statistic, with values of < 50%, 50–75%, and > 75% typically interpreted as low, moderate, and high heterogeneity, respectively [24]. A fixed-effects model was applied if I² < 50%; otherwise, a random-effects model was used. A two-sided P-value of < 0.05 was considered statistically significant. Planned subgroup analyses (e.g., by block type) were not feasible due to an insufficient number of studies in each category. In line with Cochrane guidance, had any multi-arm trials been identified, we planned to combine intervention groups that were clinically comparable (e.g., two different fascial plane blocks) to avoid unit-of-analysis error. Publication bias was assessed for outcomes comprising five or more studies [25]. While formal tests (e.g., Egger’s test) are underpowered with fewer than 10 studies, funnel plots were generated and visually inspected as an exploratory analysis to flag potential asymmetry, acknowledging its interpretative limitations [25]. Results Literature search results and general characteristics A total of 732 records were identified through the literature search across five databases. The study selection process is detailed in the PRISMA flowchart (Fig. 1). Duplicate records were removed, and 535 records were excluded during the screening of titles and abstracts. Fig. 1Study inclusion flow chart Study inclusion flow chart Summary of included study characteristics The nine included RCTs involved a total of 664 participants, with 335 allocated to receive an UGPB and 329 to control groups. The UGPBs evaluated were the erector spinae plane block (ESPB) in four studies [14, 26–28] and the serratus anterior plane block (SAPB) in four studies [29–32]. Control interventions varied, encompassing systemic analgesia alone (e.g., intravenous patient-controlled analgesia) [14, 26, 31–32], active comparator blocks (thoracic paravertebral block [27, 29] or retrolaminar block [28]), or epidural analgesia [30]. One study compared a single-shot fascial plane block to a continuous catheter-based analgesic technique [33]. Co-interventions in both groups frequently included multimodal systemic analgesia as part of standard care. The study populations consisted of adults with traumatic rib fractures, predominantly unilateral and involving multiple ribs (≥ 3). The mean age across studies ranged from the mid-30s to early 70s. The pooled population was 69.9% male (464/664) and 30.1% female (200/664), with individual study sex distributions provided in Table 1. All studies assessed pain intensity using either a Visual Analog Scale (VAS) or Numeric Rating Scale (NRS). Most studies also reported on analgesic consumption (often as morphine milligram equivalents, MME) within the first 24 h. Secondary outcomes varied, with three studies reporting arterial blood gas parameters (PaO₂ and PaCO₂) [26, 28, 29], and several assessing respiratory function, patient satisfaction, or inflammatory markers. Adverse events were explicitly reported in four studies [14, 27, 28, 31], though definitions and reporting formats were heterogeneous. Detailed characteristics of each study are presented in Table 1. Table 1General baseline dataStudy (Author, Year)Sample size & SexAge (year), EGAge (year), CGPatient PopulationIntervention Details (EG: UGPB; CG: control)Measured Outcomes (Tools)Main Study ConclusionsReported Adverse EventsLiu 2023 [29]EG:30, CG:30; Sex NR55.81 ± 16.6357.42 ± 20.24Unilateral traumatic multiple rib fractures (≥ 3 ribs)EG: SAPB, 0.375% ropivacaine 20 mLCG: TPVB, 0.375% ropivacaine 20 mLPain (VAS); PaO₂; PaCO₂SAPB and TPVB provided comparable analgesia and improvement in respiratory parameters.Not reportedYu 2024 [26]EG:29, CG:29; Total male:4242.1 ± 12.844.7 ± 12.6Elective multiple rib fracture internal fixation (ASA I/II)EG: ESPB, 0.5% ropivacaine 0.4 mL/kg + GACG: GA alone + sufentanil PCIAPulmonary function (FVC); Blood gas (PaO₂, PaCO₂, SpO₂); Pain (VAS); PCIA presses; Rescue analgesia; Inflammatory markers (IL-6, TNF-α)Preoperative ESPB improved pulmonary function, provided more effective analgesia, and reduced inflammatory response vs. GA alone.Not reportedLeasia 2021 [33]EG:16, CG:18; Male:11/1055.5 ± 30.352.3 ± 19.5Surgical stabilization of rib fractures (SSRF)EG: Single-shot fascial plane block (liposomal bupivacaine mixture)CG: Indwelling catheter for continuous 0.125% bupivacaine infusionRespiratory function (SCARF score); Daily opioid requirement (MME); Analgesia failure rate; Ventilator-free days; Pneumonia; Hospital/ICU LOSSingle-dose liposomal bupivacaine block was non-inferior to continuous catheter infusion for postop pain control and respiratory function.Not reportedElawamy 2022 [27]EG:30, CG:30; Male:25/2636.3 ± 11.4535.60 ± 12.45Unilateral multiple rib fractures, VAS ≥ 7EG: ESPB, 0.5% bupivacaine (0.3 mL/kg) + dexamethasone 8 mgCG: TPVB, 0.5% bupivacaine (0.3 mL/kg) + dexamethasone 8 mgPain (VAS)ESPB provided comparable analgesia to TPVB for acute pain relief in rib fractures.TPVB: Hypotension (20%), Bradycardia (6.67%), Vascular puncture (10%).ESPB: None.Lunden 2024 [30]EG:29, CG:30; Male:21/2452 ± 1351 ± 12Unilateral multiple rib fractures (≥ 3 ribs), NRS ≥ 4EG: Continuous SAPB, ropivacaine (2 mg/mL) bolus + infusionCG: Epidural analgesia (EA), ropivacaine (2 mg/mL) bolus + infusionPain (NRS); Pulmonary function (FEV1%); Patient satisfaction; 24 h & 48 h opioid consumptionContinuous SAPB is an effective and potentially safer alternative to epidural analgesia for rib fracture pain and pulmonary function.Not reportedPartyka 2024 [31]EG:103, CG:104; Total male:13171 ± 22.9671 ± 17.78ED patients with suspected/confirmed rib fracturesEG: Single-shot SAPB (high-volume low-concentration ropivacaine) + standardized careCG: Standardized rib fracture care only (no block)Pain (NRS); 4,12,24 h opioid consumption (MME); Pneumonia; Delirium; ICU/Hospital LOS; 30-day mortalityEarly SAPB in the ED significantly improved pain outcomes and may reduce opioid consumption and related complications.Local anesthetic systemic toxicity (one case)Ramesh 2024 [14]EG:23, CG:23; Total male:4049.48 ± 10.1951.52 ± 14.16Traumatic rib fractures in ED, NRS ≥ 4 after initial analgesiaEG: ESPB, 0.5% bupivacaine (2.5 mg/kg, max 150 mg)CG: Sham block (skin prep + pressure only, no drug)Pain (NRS); Chest expansion; Rescue opioid consumptionESPB provided significant and prolonged analgesia and reduced opioid need compared to sham.Hypotension, altered mental status, rash, seizures, dizziness, itching, headache monitored.Teksen 2021 [32]EG:30, CG:30; Total male:1850.7 ± 18.842.4 ± 15.8Rib fractures, NRS ≥ 4EG: Single-shot SAPB, 0.25% bupivacaine 30 mL + tramadol IV-PCIACG: Tramadol IV-PCIA onlyPain (NRS); 24 h total tramadol consumption; Oxygen saturation; Chronic pain at 3 monthsSAPB provided superior early pain control and opioid-sparing effect vs. IV analgesia alone.Not reportedZhao 2022 [28]EG:40, CG:40; Total male:5641 ± 26.6744 ± 29.63Internal fixation of unilateral multiple rib fracturesEG: ESPB, 0.5% ropivacaine 20 mL after GACG: RLB, 0.5% ropivacaine 20 mL after GAPain (VAS); Intraoperative remifentanil & postoperative morphine consumption; Diaphragmatic activity; Blood gas analysisESPB and RLB provided similar postoperative analgesia and opioid-sparing effects.Pleural perforation, hematoma, intraspinal spread, nausea/vomiting recorded.Abbreviations (alphabetical order): ASA American Society of Anesthesiologists, CG Control group, EA Epidural analgesia, ED Emergency department, EG Experimental group, ESPB Erector spinae plane block, FEV1% Forced expiratory volume in 1 second percent, FVC Forced vital capacity, GA General anesthesia, ICU Intensive care unit, LOS Length of stay, MME Morphine milligram equivalents, NRS Numeric rating scale, PACU Post-anesthesia care unit, PaCO₂ Arterial partial pressure of carbon dioxide, PaO₂ Arterial partial pressure of oxygen, PCIA Patient-controlled intravenous analgesia, RLB Retrolaminar block, SAPB Serratus anterior plane block, SpO₂ Oxygen saturation, SSRF Surgical stabilization of rib fractures, TPVB Thoracic paravertebral block, VAS Visual analog scale Table 1General baseline dataStudy (Author, Year)Sample size & SexAge (year), EGAge (year), CGPatient PopulationIntervention Details (EG: UGPB; CG: control)Measured Outcomes (Tools)Main Study ConclusionsReported Adverse EventsLiu 2023 [29]EG:30, CG:30; Sex NR55.81 ± 16.6357.42 ± 20.24Unilateral traumatic multiple rib fractures (≥ 3 ribs)EG: SAPB, 0.375% ropivacaine 20 mLCG: TPVB, 0.375% ropivacaine 20 mLPain (VAS); PaO₂; PaCO₂SAPB and TPVB provided comparable analgesia and improvement in respiratory parameters.Not reportedYu 2024 [26]EG:29, CG:29; Total male:4242.1 ± 12.844.7 ± 12.6Elective multiple rib fracture internal fixation (ASA I/II)EG: ESPB, 0.5% ropivacaine 0.4 mL/kg + GACG: GA alone + sufentanil PCIAPulmonary function (FVC); Blood gas (PaO₂, PaCO₂, SpO₂); Pain (VAS); PCIA presses; Rescue analgesia; Inflammatory markers (IL-6, TNF-α)Preoperative ESPB improved pulmonary function, provided more effective analgesia, and reduced inflammatory response vs. GA alone.Not reportedLeasia 2021 [33]EG:16, CG:18; Male:11/1055.5 ± 30.352.3 ± 19.5Surgical stabilization of rib fractures (SSRF)EG: Single-shot fascial plane block (liposomal bupivacaine mixture)CG: Indwelling catheter for continuous 0.125% bupivacaine infusionRespiratory function (SCARF score); Daily opioid requirement (MME); Analgesia failure rate; Ventilator-free days; Pneumonia; Hospital/ICU LOSSingle-dose liposomal bupivacaine block was non-inferior to continuous catheter infusion for postop pain control and respiratory function.Not reportedElawamy 2022 [27]EG:30, CG:30; Male:25/2636.3 ± 11.4535.60 ± 12.45Unilateral multiple rib fractures, VAS ≥ 7EG: ESPB, 0.5% bupivacaine (0.3 mL/kg) + dexamethasone 8 mgCG: TPVB, 0.5% bupivacaine (0.3 mL/kg) + dexamethasone 8 mgPain (VAS)ESPB provided comparable analgesia to TPVB for acute pain relief in rib fractures.TPVB: Hypotension (20%), Bradycardia (6.67%), Vascular puncture (10%).ESPB: None.Lunden 2024 [30]EG:29, CG:30; Male:21/2452 ± 1351 ± 12Unilateral multiple rib fractures (≥ 3 ribs), NRS ≥ 4EG: Continuous SAPB, ropivacaine (2 mg/mL) bolus + infusionCG: Epidural analgesia (EA), ropivacaine (2 mg/mL) bolus + infusionPain (NRS); Pulmonary function (FEV1%); Patient satisfaction; 24 h & 48 h opioid consumptionContinuous SAPB is an effective and potentially safer alternative to epidural analgesia for rib fracture pain and pulmonary function.Not reportedPartyka 2024 [31]EG:103, CG:104; Total male:13171 ± 22.9671 ± 17.78ED patients with suspected/confirmed rib fracturesEG: Single-shot SAPB (high-volume low-concentration ropivacaine) + standardized careCG: Standardized rib fracture care only (no block)Pain (NRS); 4,12,24 h opioid consumption (MME); Pneumonia; Delirium; ICU/Hospital LOS; 30-day mortalityEarly SAPB in the ED significantly improved pain outcomes and may reduce opioid consumption and related complications.Local anesthetic systemic toxicity (one case)Ramesh 2024 [14]EG:23, CG:23; Total male:4049.48 ± 10.1951.52 ± 14.16Traumatic rib fractures in ED, NRS ≥ 4 after initial analgesiaEG: ESPB, 0.5% bupivacaine (2.5 mg/kg, max 150 mg)CG: Sham block (skin prep + pressure only, no drug)Pain (NRS); Chest expansion; Rescue opioid consumptionESPB provided significant and prolonged analgesia and reduced opioid need compared to sham.Hypotension, altered mental status, rash, seizures, dizziness, itching, headache monitored.Teksen 2021 [32]EG:30, CG:30; Total male:1850.7 ± 18.842.4 ± 15.8Rib fractures, NRS ≥ 4EG: Single-shot SAPB, 0.25% bupivacaine 30 mL + tramadol IV-PCIACG: Tramadol IV-PCIA onlyPain (NRS); 24 h total tramadol consumption; Oxygen saturation; Chronic pain at 3 monthsSAPB provided superior early pain control and opioid-sparing effect vs. IV analgesia alone.Not reportedZhao 2022 [28]EG:40, CG:40; Total male:5641 ± 26.6744 ± 29.63Internal fixation of unilateral multiple rib fracturesEG: ESPB, 0.5% ropivacaine 20 mL after GACG: RLB, 0.5% ropivacaine 20 mL after GAPain (VAS); Intraoperative remifentanil & postoperative morphine consumption; Diaphragmatic activity; Blood gas analysisESPB and RLB provided similar postoperative analgesia and opioid-sparing effects.Pleural perforation, hematoma, intraspinal spread, nausea/vomiting recorded.Abbreviations (alphabetical order): ASA American Society of Anesthesiologists, CG Control group, EA Epidural analgesia, ED Emergency department, EG Experimental group, ESPB Erector spinae plane block, FEV1% Forced expiratory volume in 1 second percent, FVC Forced vital capacity, GA General anesthesia, ICU Intensive care unit, LOS Length of stay, MME Morphine milligram equivalents, NRS Numeric rating scale, PACU Post-anesthesia care unit, PaCO₂ Arterial partial pressure of carbon dioxide, PaO₂ Arterial partial pressure of oxygen, PCIA Patient-controlled intravenous analgesia, RLB Retrolaminar block, SAPB Serratus anterior plane block, SpO₂ Oxygen saturation, SSRF Surgical stabilization of rib fractures, TPVB Thoracic paravertebral block, VAS Visual analog scale General baseline data EG: SAPB, 0.375% ropivacaine 20 mL CG: TPVB, 0.375% ropivacaine 20 mL EG: ESPB, 0.5% ropivacaine 0.4 mL/kg + GA CG: GA alone + sufentanil PCIA EG: Single-shot fascial plane block (liposomal bupivacaine mixture) CG: Indwelling catheter for continuous 0.125% bupivacaine infusion EG: ESPB, 0.5% bupivacaine (0.3 mL/kg) + dexamethasone 8 mg CG: TPVB, 0.5% bupivacaine (0.3 mL/kg) + dexamethasone 8 mg TPVB: Hypotension (20%), Bradycardia (6.67%), Vascular puncture (10%). ESPB: None. EG: Continuous SAPB, ropivacaine (2 mg/mL) bolus + infusion CG: Epidural analgesia (EA), ropivacaine (2 mg/mL) bolus + infusion EG: Single-shot SAPB (high-volume low-concentration ropivacaine) + standardized care CG: Standardized rib fracture care only (no block) EG: ESPB, 0.5% bupivacaine (2.5 mg/kg, max 150 mg) CG: Sham block (skin prep + pressure only, no drug) EG: Single-shot SAPB, 0.25% bupivacaine 30 mL + tramadol IV-PCIA CG: Tramadol IV-PCIA only EG: ESPB, 0.5% ropivacaine 20 mL after GA CG: RLB, 0.5% ropivacaine 20 mL after GA Abbreviations (alphabetical order): ASA American Society of Anesthesiologists, CG Control group, EA Epidural analgesia, ED Emergency department, EG Experimental group, ESPB Erector spinae plane block, FEV1% Forced expiratory volume in 1 second percent, FVC Forced vital capacity, GA General anesthesia, ICU Intensive care unit, LOS Length of stay, MME Morphine milligram equivalents, NRS Numeric rating scale, PACU Post-anesthesia care unit, PaCO₂ Arterial partial pressure of carbon dioxide, PaO₂ Arterial partial pressure of oxygen, PCIA Patient-controlled intravenous analgesia, RLB Retrolaminar block, SAPB Serratus anterior plane block, SpO₂ Oxygen saturation, SSRF Surgical stabilization of rib fractures, TPVB Thoracic paravertebral block, VAS Visual analog scale Risk of bias assessment in included studies The risk of bias for the nine included studies was assessed using the Cochrane RoB 2.0 tool (Fig. 2). Across the nine studies, the percentages of low risk of bias for each domain were as follows: randomization process (88.9%), deviations from intended interventions (66.7%), missing outcome data (88.9%), measurement of the outcome (66.7%), and selection of the reported result (11.1%). Applying the tool’s algorithm, studies with “some concerns” in two or more domains were judged to be at an overall high risk of bias. Consequently, four studies [14, 26, 29, 32] were rated at high overall risk of bias. The concerns in these studies primarily pertained to the randomization process, allocation concealment, and/or blinding of participants and personnel. The remaining five studies were judged to raise some concerns in at least one domain, with no studies being at overall low risk. The core outcome of pain scores was considered at low risk of detection bias in the majority of studies. Fig. 2Risk of bias assessment. A Risk of bias summary: reviewers’ judgements about each risk of bias item for each included study. B Risk of bias graph: reviewers’ judgements about each risk of bias item presented as percentages across all included studies Risk of bias assessment. A Risk of bias summary: reviewers’ judgements about each risk of bias item for each included study. B Risk of bias graph: reviewers’ judgements about each risk of bias item presented as percentages across all included studies Pain score A total of 7 RCTs [14, 26–30, 32], involving 423 participants, compared pain scores between patients receiving a UGPB (including ESPB and SAPB techniques) and those receiving standard care (systemic analgesia). The meta-analysis indicated that the UGPB group had significantly lower pain scores than the control group (SMD = -0.44, 95% CI: [-0.72, -0.16; UGPB group n = 211, control group n = 212], p < 0.01), with moderate heterogeneity (I² = 51%) (Fig. 3A). A leave-one-out sensitivity analysis (Fig. 3B) was performed. The exclusion of any single study did not substantially alter the overall result. The pooled SMD ranged from − 0.38 (95% CI: -0.68, -0.09) to -0.49 (95% CI: -0.78, -0.20), which remained statistically significant (all p < 0.05) and consistent with the primary analysis (SMD = -0.44), indicating the robustness of the finding. Fig. 3Meta-analysis and sensitivity analysis of pain scores. A Forest plot for pain scores at 24 h post-intervention. B Sensitivity analysis evaluating the robustness of the pooled estimate for pain scores. Results in panel A are presented as standardized mean difference (SMD) with 95% confidence interval (CI) Meta-analysis and sensitivity analysis of pain scores. A Forest plot for pain scores at 24 h post-intervention. B Sensitivity analysis evaluating the robustness of the pooled estimate for pain scores. Results in panel A are presented as standardized mean difference (SMD) with 95% confidence interval (CI) Analgesic use For analgesic use, data were reported in 7 studies [14, 27, 28, 30–33]. These studies investigated the effect of various UGPB approaches on the total amount of supplemental systemic analgesics required (i.e., opioid-sparing effect). The meta-analysis showed no statistically significant difference between groups (SMD = -0.09; 95% CI: [-1.61, 1.43]; P > 0.05; UGPB group n = 271, control group n = 275), with considerable heterogeneity observed (I² = 96%). (Fig. 4A). Fig. 4Meta-analyses for analgesic consumption and respiratory parameters. A Total analgesic consumption within 24 h post-intervention. (B) Arterial partial pressure of oxygen (PaO₂). C Arterial partial pressure of carbon dioxide (PaCO₂). All results are presented as standardized mean difference (SMD) with 95% confidence interval (CI) Meta-analyses for analgesic consumption and respiratory parameters. A Total analgesic consumption within 24 h post-intervention. (B) Arterial partial pressure of oxygen (PaO₂). C Arterial partial pressure of carbon dioxide (PaCO₂). All results are presented as standardized mean difference (SMD) with 95% confidence interval (CI) Blood gas analysis A total of 3 studies [26, 28, 29] reported on PaO₂ and PaCO₂, involving 198 patients. The meta-analysis of PaO₂ levels using a fixed-effect model showed no significant difference between the two groups (SMD = 0.04, 95% CI: -0.24 to 0.32), with no heterogeneity (I² = 0%; UGPB group n = 99, control group n = 99; Fig. 4B). This suggests that ultrasound-guided plane block has no significant impact on patients’ oxygenation function. For PaCO₂ levels, the meta-analysis showed no statistically significant difference between groups (SMD = -0.02, 95% CI: -0.56 to 0.61; UGPB group n = 99, control group n = 99; Fig. 4C). However, this result should be interpreted with caution due to considerable heterogeneity (I² = 75%) and the small number of included studies (n = 3), which limit the generalizability and certainty of this finding.(Fig. 4BC). Adverse events Adverse events were reported in four studies [14, 27, 28, 31]. The reported follow-up periods varied: one study followed patients until hospital discharge [27], another until 30 days [31], and the remaining two did not specify the follow-up duration [14, 28]. A quantitative meta-analysis was considered but deemed not feasible. This decision was due to substantial heterogeneity in the definitions, types, and reporting formats of adverse events across studies, coupled with insufficient dichotomous count data available for pooling from the limited number of studies. Therefore, a qualitative synthesis was performed. Specific adverse events included: hypotension (20%), bradycardia (6.67%), and vascular puncture (10%) in the thoracic paravertebral block group, with no such events in the ESPB group [27]; one case of local anesthetic systemic toxicity in the SAPB group [31]; and monitored events including hypotension, altered mental status, rash, seizures, dizziness, itching, and headache [14]; and procedure-related events including pleural perforation, hematoma, and nausea/vomiting [28]. Exact event counts were not reported in most studies. Explicit descriptions of monitoring or safeguarding procedures were provided in one study [14]. The most common events included nausea, vomiting, and pruritus, with no clear difference in incidence between the UGPB and control groups. One study [27] reported procedure-related events, noting hypotension and vascular puncture in the thoracic paravertebral block group but not in the erector spinae plane block group. The overall evidence suggests that serious adverse events are uncommon, but the limited and inconsistent reporting prevents definitive conclusions regarding safety. Publication bias For outcomes with more than five included studies, this research performed publication bias assessment. Funnel plots for the primary outcomes appeared largely symmetrical upon visual inspection, suggesting no obvious evidence of publication bias (Figs. 5 and 6). Egger’s regression test was conducted for each of these outcomes, and all p-values were greater than 0.05, indicating no significant small-study effects and supporting a low risk of publication bias. Fig. 5Funnel plot of pain score Funnel plot of pain score Fig. 6Funnel plot of analgesic used Funnel plot of analgesic used GRADE assessment of the evidence The certainty of the evidence for each primary outcome was assessed using the GRADE framework and is summarized in Table 2. The evidence for the reduction in pain scores was graded as low certainty, due to concerns regarding risk of bias and inconsistency (moderate heterogeneity). The evidence for analgesic consumption was graded as very low certainty, due to serious concerns regarding risk of bias, very serious inconsistency (extreme heterogeneity), and imprecision. The evidence for both PaO₂ and PaCO₂ was graded as very low certainty, due to serious concerns regarding risk of bias, indirectness (only 3 small studies), and very serious imprecision. Table 2GRADE summary of findings tableOutcomeNo. of studies (participants)Effect estimate (95% CI)Certainty of evidence (GRADE)Plain language summaryPain score7 (423)SMD − 0.44 (-0.72 to -0.16)⨁⨁◯◯ LowUGPB likely reduces pain scores at 24 h post-intervention compared with standard care.Analgesic consumption7 (546)SMD − 0.09 (-1.61 to 1.43)⨁◯◯◯ Very lowThe effect of UGPB on analgesic consumption is uncertain.PaO₂3 (198)SMD 0.04 (-0.24 to 0.32)⨁◯◯◯ Very lowUGPB does not appear to affect PaO₂ levels, but the evidence is very uncertain.PaCO₂3 (198)SMD − 0.02 (-0.56 to 0.61)⨁◯◯◯ Very lowThe effect of UGPB on PaCO₂ levels is uncertain due to inconsistency and imprecision.Certainty of evidence was assessed using the GRADE frameworkSMD Standardized mean difference, CI Confidence intervalGRADE certainty ratings: Low ⨁⨁◯◯ (further research is likely to have an important impact on confidence in the estimate and may change the estimate); Very low ⨁◯◯◯ (the estimate is very uncertain) Table 2GRADE summary of findings tableOutcomeNo. of studies (participants)Effect estimate (95% CI)Certainty of evidence (GRADE)Plain language summaryPain score7 (423)SMD − 0.44 (-0.72 to -0.16)⨁⨁◯◯ LowUGPB likely reduces pain scores at 24 h post-intervention compared with standard care.Analgesic consumption7 (546)SMD − 0.09 (-1.61 to 1.43)⨁◯◯◯ Very lowThe effect of UGPB on analgesic consumption is uncertain.PaO₂3 (198)SMD 0.04 (-0.24 to 0.32)⨁◯◯◯ Very lowUGPB does not appear to affect PaO₂ levels, but the evidence is very uncertain.PaCO₂3 (198)SMD − 0.02 (-0.56 to 0.61)⨁◯◯◯ Very lowThe effect of UGPB on PaCO₂ levels is uncertain due to inconsistency and imprecision.Certainty of evidence was assessed using the GRADE frameworkSMD Standardized mean difference, CI Confidence intervalGRADE certainty ratings: Low ⨁⨁◯◯ (further research is likely to have an important impact on confidence in the estimate and may change the estimate); Very low ⨁◯◯◯ (the estimate is very uncertain) GRADE summary of findings table Certainty of evidence was assessed using the GRADE framework SMD Standardized mean difference, CI Confidence interval GRADE certainty ratings: Low ⨁⨁◯◯ (further research is likely to have an important impact on confidence in the estimate and may change the estimate); Very low ⨁◯◯◯ (the estimate is very uncertain) Discussion Key findings This systematic review and meta-analysis suggests that ultrasound-guided plane block (UGPB) may be associated with a reduction in pain scores at 24 h post-intervention compared to standard systemic analgesia. However, this finding must be interpreted cautiously given the small-to-moderate effect size (SMD − 0.44, 95% CI: -0.72 to -0.16), the wide confidence interval, and the low certainty of the evidence. Furthermore, this analgesic efficacy was achieved without statistically significant alterations in respiratory parameters (PaO₂ and PaCO₂) in the limited number of studies reporting these outcomes. In contrast, the effect of UGPB on analgesic consumption was not statistically significant and exhibited extreme heterogeneity (I² = 96%), precluding a definitive conclusion on its opioid-sparing effect. The safety profile of UGPB appears favorable, with our available data showing no significant increase in the risk of adverse events. While the observed pain reduction may be clinically meaningful in some patients, particularly given the absence of respiratory compromise, the low certainty of evidence suggests that further research is likely to change the estimate of effect. Clinically, UGPB may offer effective pain relief without compromising respiratory function, and could be considered as a component of multimodal analgesia in rib fracture management. Potential mechanisms of action of UGPB The analgesic effect of UGPB is primarily attributed to the spread of local anesthetic within the fascial planes, which targets the dorsal and ventral rami of the spinal nerves [12]. Real-time, high-resolution ultrasound guidance is fundamental to this technique, as it ensures precise deposition of the anesthetic into the target interfascial plane. This precision not only enhances the block’s success rate but also underlies its safety, contributing to the very low rates of serious complications such as pneumothorax, vascular puncture, or local anesthetic systemic toxicity reported in the included studies [13, 34]. Outcome-specific comparisons with other block techniques Our finding of significant pain reduction aligns with the known efficacy of other well-established regional techniques for rib fractures, such as thoracic paravertebral block and epidural analgesia. However, UGPB offers a distinct and potentially safer profile. Unlike paravertebral blocks, which carry a non-trivial risk of pneumothorax and sympathetic blockade, or epidurals, which can cause hypotension and urinary retention, UGPB is performed superficial to the pleura and away from the neuraxis, thereby mitigating these specific risks. The high heterogeneity observed in our analysis of analgesic consumption and respiratory outcomes may partly reflect the pooling of different UGPB approaches (e.g., erector spinae plane block vs. serratus anterior plane block), which have different anatomical targets and potentially different effects on respiratory musculature, a nuance that future studies should aim to clarify. The heterogeneity in analgesic consumption could be attributed to several factors, including variations in block technique and local anesthetic protocols [35], diverse patient characteristics and pain levels [36], as well as differences in the analgesic regimens used in control groups across studies [36]. Although we used SMD to account for unit variations, heterogeneity remained high, potentially due to differences in anesthetic concentration/volume and patient-level factors [18]. The principal advantage of UGPB lies in its enhanced safety profile, technical accessibility, and applicability across diverse clinical settings. The ultrasonic visualization of the needle tip and tissue planes reduces the technical difficulty and variability associated with traditional blind or landmark-based techniques. This makes UGPB a valuable tool not only in the operating room but also in dynamic and time-sensitive environments like the emergency department or the intensive care unit [37]. The ability to provide profound analgesia without significant respiratory depression or the systemic side effects of opioids (e.g., sedation, nausea) can facilitate earlier mobilization and improved pulmonary hygiene, which are critical for preventing complications in patients with rib fractures. Comparative advantages of UGPB Beyond the statistical findings, several practical advantages of UGPB warrant consideration. First, the safety profile of UGPB is favorable compared with traditional regional techniques such as thoracic paravertebral block or epidural analgesia. The ultrasound-guided fascial plane approach positions the needle tip superficial to the pleura and away from major neurovascular structures, substantially reducing the risks of pneumothorax, vascular puncture, and neuraxial complications [13, 34]. This safety advantage makes UGPB particularly attractive in patients with coagulopathy or those receiving antithrombotic therapy, where epidural or paravertebral blocks may be relatively contraindicated. Second, UGPB offers high feasibility and a relatively shallow learning curve. Real-time ultrasound visualization of the target fascial plane and local anesthetic spread allows practitioners with basic ultrasound skills to perform the block effectively [12]. This accessibility expands the clinical settings in which UGPB can be deployed, including emergency departments, intensive care units, and even prehospital environments, where timely pain control is critical [37]. Third, by providing effective analgesia without significant respiratory depression or sedation, UGPB may facilitate early mobilization, improve pulmonary hygiene, and reduced intensive care unit length of stay. Patients who experience less pain during deep breathing and coughing are more likely to participate in chest physiotherapy, thereby lowering the risk of atelectasis, pneumonia, and other pulmonary complications [8]. Although our meta-analysis did not directly measure these recovery outcomes, the observed pain reduction (SMD = -0.44) and stable blood gas parameters indirectly support these clinical benefits. Fourth, regarding cost considerations, UGPB may offer economic advantages over continuous catheter-based techniques (e.g., epidural or paravertebral catheters) or prolonged intravenous opioid infusions. A single-shot fascial plane block requires no infusion pump, daily catheter maintenance, or dedicated acute pain service follow-up, potentially reducing healthcare resource utilization [33]. However, formal cost-effectiveness analyses are lacking, and future research should include economic outcomes. Study limitations and sources of bias The interpretations of our findings must be considered in the context of several limitations. It should be noted, however, that a sensitivity analysis supported the robustness of the primary pain outcome. First, the meta-analysis was constrained by a limited number of studies, particularly for the outcomes of blood gas analysis and adverse events, resulting in low statistical power and very low certainty of evidence for these endpoints. Second, considerable clinical and methodological heterogeneity was present, primarily stemming from the pooling of different UGPB techniques, variations in local anesthetic protocols (type, volume, concentration), and differences in the analgesic regimens of control groups. Furthermore, the assessment of safety was limited by the heterogeneous and often incomplete reporting of adverse events across studies, which prevented a meaningful quantitative meta-analysis and underscores the need for standardized safety reporting in future trials. Third, the use of the standardized mean difference (SMD) as the summary statistic, while methodologically consistent and necessary for pooling diverse measures of analgesic consumption, limits the direct clinical interpretability of the effect size for pain scores. An SMD does not translate to a specific unit change on the original scales (e.g., VAS or NRS), which may obscure the precise clinical magnitude of the benefit. Consequently, while the pooled SMD of -0.44 for pain reduction is statistically significant and corresponds to a ‘moderate’ effect size according to conventional benchmarks (e.g., Cohen’s d), a definitive statement about its clinical significance for an individual patient with rib fractures remains challenging based on the current analysis. Although planned, the small number of studies for each specific block type precluded meaningful subgroup analysis or meta-regression to explore these sources of heterogeneity. Fourth, the overall risk of bias was a concern in several included studies, primarily due to inadequate reporting of allocation concealment and blinding, which could potentially overestimate treatment effects. Specifically, four studies were judged to be at high overall risk of bias according to the Cochrane RoB 2.0 algorithm: one due to a high risk in a single domain, and three due to some concerns in two or more domains. Finally, the focus on short-term outcomes (e.g., 24-hour pain scores) limits our understanding of the long-term impact of UGPB on chronic pain development and functional recovery. Varying follow-up periods across studies precluded a systematic assessment of these important long-term outcomes. Effective analgesia is crucial for both short-term recovery and long-term prognosis [38]. The high heterogeneity, particularly for analgesic consumption, underscores significant variations in clinical practice (e.g., block techniques, analgesic protocols). Future research employing standardized protocols and larger samples is needed to clarify the sources of this heterogeneity and to better define the role of UGPB. Conclusion In conclusion, this meta-analysis suggests that ultrasound-guided plane block may be an effective analgesic technique for patients with rib fractures, associated with significantly reduced pain scores. However, its impact on systemic analgesic consumption remains uncertain due to non-significant and highly heterogeneous results, and the potential for UGPB to lower drug-related side effects is not yet substantiated by the current evidence. Regarding safety, UGPB was not associated with significant alterations in blood gas parameters in our analysis. While this is a reassuring finding, it does not constitute robust evidence of safety given the limited data. These findings must be interpreted in the context of the study’s limitations, including the clinical heterogeneity of the interventions, the risk of bias in some included trials, and the limited number of studies for key outcomes. Consequently, the current evidence is not sufficient to draw definitive, high-certainty conclusions. Future high-quality, large-scale RCTs with standardized protocols and long-term follow-up are essential to confirm these findings, establish the comparative effectiveness of different block approaches, and optimize dosing regimens for clinical practice. Pending further confirmation, ultrasound-guided plane block can be considered a component of multimodal analgesia for rib fractures. Supplementary Information Supplementary Material 1. Supplementary Material 1.